JP2020518600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518600A5 JP2020518600A5 JP2019559836A JP2019559836A JP2020518600A5 JP 2020518600 A5 JP2020518600 A5 JP 2020518600A5 JP 2019559836 A JP2019559836 A JP 2019559836A JP 2019559836 A JP2019559836 A JP 2019559836A JP 2020518600 A5 JP2020518600 A5 JP 2020518600A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- preparation according
- approximately
- tigit antibody
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023189493A JP2024016177A (ja) | 2017-05-02 | 2023-11-06 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500278P | 2017-05-02 | 2017-05-02 | |
| US62/500,278 | 2017-05-02 | ||
| PCT/US2018/030516 WO2018204405A1 (en) | 2017-05-02 | 2018-05-01 | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189493A Division JP2024016177A (ja) | 2017-05-02 | 2023-11-06 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518600A JP2020518600A (ja) | 2020-06-25 |
| JP2020518600A5 true JP2020518600A5 (enExample) | 2021-05-20 |
| JP7402693B2 JP7402693B2 (ja) | 2023-12-21 |
Family
ID=64016405
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559836A Active JP7402693B2 (ja) | 2017-05-02 | 2018-05-01 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
| JP2023189493A Pending JP2024016177A (ja) | 2017-05-02 | 2023-11-06 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189493A Pending JP2024016177A (ja) | 2017-05-02 | 2023-11-06 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200354453A1 (enExample) |
| EP (1) | EP3618855A4 (enExample) |
| JP (2) | JP7402693B2 (enExample) |
| KR (1) | KR102770786B1 (enExample) |
| CN (1) | CN110603052A (enExample) |
| AU (1) | AU2018261080A1 (enExample) |
| BR (1) | BR112019022698A2 (enExample) |
| CA (1) | CA3061050A1 (enExample) |
| CL (1) | CL2019003145A1 (enExample) |
| CO (1) | CO2019012356A2 (enExample) |
| IL (1) | IL270175B2 (enExample) |
| MA (1) | MA50661A (enExample) |
| MX (1) | MX2019013033A (enExample) |
| SG (2) | SG11201909941QA (enExample) |
| WO (1) | WO2018204405A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CN115925931A (zh) * | 2015-08-14 | 2023-04-07 | 默沙东公司 | 抗tigit抗体 |
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| MX2021004356A (es) | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. |
| MA54089A (fr) | 2018-10-31 | 2022-02-09 | Merck Sharp & Dohme | Anticorps anti-pd-1 humain et procédés d'utilisation associés |
| JP7503056B6 (ja) | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤 |
| US20210380694A1 (en) * | 2018-11-07 | 2021-12-09 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| MX2021007047A (es) * | 2018-12-14 | 2021-10-26 | Morphosys Ag | Formulaciones de anticuerpos. |
| CA3139641A1 (en) * | 2019-06-13 | 2020-12-17 | Green Cross Corporation | Antibody to tigit and use thereof |
| EP3999537A1 (en) * | 2019-07-19 | 2022-05-25 | Ichnos Sciences SA | Lyophilized antibody formulation |
| CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
| CN115052622B (zh) * | 2020-01-21 | 2026-03-06 | 夏尔巴生物技术(杭州)有限公司 | 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途 |
| MX2022008949A (es) * | 2020-01-24 | 2022-08-15 | Regeneron Pharma | Formulacion de anticuerpos estable. |
| CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| TW202210514A (zh) * | 2020-06-02 | 2022-03-16 | 美商阿克思生物科學有限公司 | 針對tigit的抗體 |
| WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| CN111718415B (zh) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | 一种抗tigit纳米抗体及其应用 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| JP2023539736A (ja) * | 2020-08-25 | 2023-09-19 | ブリストル－マイヤーズ スクイブ カンパニー | 拮抗性ｃｄ４０モノクローナル抗体で自己免疫性疾患を処置する方法 |
| AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
| PT4267105T (pt) * | 2020-12-28 | 2025-04-30 | Bristol Myers Squibb Co | Composições de anticorpos e métodos de utilização das mesmas |
| EP4293045A4 (en) * | 2021-01-14 | 2024-12-11 | Shanghai Junshi Biosciences Co., Ltd. | PHARMACEUTICAL COMPOSITION OF ANTI-TIGIT ANTIBODY AND ITS APPLICATION |
| AU2022212007A1 (en) | 2021-01-29 | 2023-09-07 | Merck Sharp & Dohme Llc | Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| CA3217279A1 (en) | 2021-05-04 | 2022-11-10 | Olga Ignatovich | Anti-tigit antibodies and methods of use thereof |
| US20240352153A1 (en) * | 2021-07-23 | 2024-10-24 | Akeso Biopharma, Inc | Pharmaceutical composition and use |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| CN114106182B (zh) * | 2022-01-26 | 2022-05-17 | 中山康方生物医药有限公司 | 抗tigit的抗体及其用途 |
| WO2023163968A1 (en) * | 2022-02-24 | 2023-08-31 | Merck Sharp & Dohme Llc | Stable formulations of a multivalent vhh based cytotoxic t lymphocyte associated antigen 4 (ctla4) binder binding to human ctla4 and methods of use thereof |
| TW202345902A (zh) * | 2022-04-14 | 2023-12-01 | 瑞士商百濟神州瑞士有限責任公司 | 含有ｐｄ－１抗體的穩定高濃度精胺酸配製物及其使用方法 |
| JP2025523387A (ja) | 2022-06-07 | 2025-07-23 | ジェネンテック， インコーポレイテッド | 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法 |
| WO2024030458A2 (en) * | 2022-08-04 | 2024-02-08 | Merck Sharp & Dohme Llc | Methods for determining one or more critical quality attributes of co-formulated antibodies |
| JP2026502936A (ja) * | 2022-12-27 | 2026-01-27 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗ｔｉｇｉｔ抗体を含む医薬製剤 |
| WO2025166550A1 (zh) * | 2024-02-06 | 2025-08-14 | 香港北恒生物科技有限公司 | 工程化细胞及其用途 |
| CN121003695A (zh) * | 2024-05-24 | 2025-11-25 | 百奥泰生物制药股份有限公司 | 抗tigit抗体和抗pd-1抗体联合治疗肿瘤 |
| WO2025248110A1 (en) | 2024-05-31 | 2025-12-04 | Replimune Limited | An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2665567C (en) * | 2006-10-06 | 2012-07-03 | Amgen Inc. | Stable formulations |
| WO2011008770A2 (en) * | 2009-07-14 | 2011-01-20 | Biogen Idec Ma Inc. | Methods for inhibiting yellow color and peroxide formation in a composition |
| EP2399604A1 (en) * | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| WO2012135408A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| TWI888366B (zh) | 2013-07-16 | 2025-07-01 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
| CA2957722C (en) * | 2014-08-19 | 2022-05-31 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| CA2998589A1 (en) * | 2015-09-14 | 2017-03-23 | Compass Therapeutics Llc | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-.beta. |
| EP3394099A4 (en) * | 2015-12-22 | 2019-11-27 | Merck Sharp & Dohme Corp. | Formulations of Manipulated Anti- IL-10 Antibodies |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
| CA3060695A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
-
2018
- 2018-05-01 SG SG11201909941Q patent/SG11201909941QA/en unknown
- 2018-05-01 EP EP18793797.4A patent/EP3618855A4/en active Pending
- 2018-05-01 BR BR112019022698A patent/BR112019022698A2/pt unknown
- 2018-05-01 MA MA050661A patent/MA50661A/fr unknown
- 2018-05-01 SG SG10202111905PA patent/SG10202111905PA/en unknown
- 2018-05-01 IL IL270175A patent/IL270175B2/en unknown
- 2018-05-01 WO PCT/US2018/030516 patent/WO2018204405A1/en not_active Ceased
- 2018-05-01 JP JP2019559836A patent/JP7402693B2/ja active Active
- 2018-05-01 CN CN201880029167.7A patent/CN110603052A/zh active Pending
- 2018-05-01 KR KR1020197035375A patent/KR102770786B1/ko active Active
- 2018-05-01 MX MX2019013033A patent/MX2019013033A/es unknown
- 2018-05-01 US US16/610,188 patent/US20200354453A1/en not_active Abandoned
- 2018-05-01 AU AU2018261080A patent/AU2018261080A1/en not_active Abandoned
- 2018-05-01 CA CA3061050A patent/CA3061050A1/en active Pending
-
2019
- 2019-10-30 CL CL2019003145A patent/CL2019003145A1/es unknown
- 2019-11-01 CO CONC2019/0012356A patent/CO2019012356A2/es unknown
-
2023
- 2023-11-06 JP JP2023189493A patent/JP2024016177A/ja active Pending
-
2024
- 2024-01-25 US US18/422,352 patent/US20240182573A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016177A5 (enExample) | ||
| US20240182573A1 (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP2020518598A5 (enExample) | ||
| US20250074985A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP2020518599A5 (enExample) | ||
| JP6014116B2 (ja) | ヒト・プログラム死受容体ｐｄ−１に対する抗体の安定製剤および関連治療 | |
| JP2020509031A5 (enExample) | ||
| JP2016533335A5 (enExample) | ||
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| BR112021005868A2 (pt) | Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g | |
| JP2021517129A5 (enExample) | ||
| CN111050791A (zh) | 用于抗tim-3抗体的给药方案及其用途 | |
| RU2012131099A (ru) | Препарат антитела | |
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| EA031436B1 (ru) | Водная фармацевтическая композиция, содержащий ее предварительно заполненный шприц и применение композиции в лечении аутоиммунных заболеваний | |
| JP2018529328A5 (enExample) | ||
| RU2745814C1 (ru) | Водная фармацевтическая композиция левилимаба и ее применение | |
| RU2024131867A (ru) | Фармацевтические составы анти-ilt4 антитела или его антигенсвязывающего фрагмента и способы применения | |
| RU2024131854A (ru) | Стабильные составы анти-ilt4 антител или их антигенсвязывающих фрагментов в комбинации с анти-pd-1 антителами и способы их применения | |
| TH1901006940A (th) | สูตรตำรับที่คงตัวของแอนติบอดีต้าน-ctla4 ชนิดเดียวและร่วมกับโปรแกรมเดธรีเซพเตอร์ 1 (pd-1) แอนติบอดี และวิธีการของการใช้งานของสิ่งนั้น | |
| WO2025056014A1 (zh) | 包含抗pd-1抗体和第二抗体的药物组合物 | |
| RU2024133531A (ru) | Стабильные высококонцентрированные составы на основе аргинина, содержащие антитело к pd-1, и способы их применения | |
| AR130954A1 (es) | Composiciones de anticuerpo anti-ctla y métodos relacionados | |
| TW202229333A (zh) | 冠狀病毒結合分子及其使用方法 | |
| WO2025056011A1 (zh) | 包含抗pd-1抗体和第二抗体的药物组合物 |